ИНСЭРМ (Институт Насьональ де ла Сант эт де ла Решерш Медикаль) (FR)
发明人:
БЕАР-КОАН Франсин (FR)
申请号：
RU2013105016/15
公开号：
RU2013105016A
申请日:
2011.08.08
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A pharmaceutical composition comprising microbubbles of an echo contrast agent and a targeted therapeutic nucleic acid for use in a method for treating eye diseases in a subject, wherein said method comprises the following steps: i) delivering said pharmaceutical composition to the ciliary muscle of a subject and ii) exposing the area, into which the pharmaceutical composition is delivered, by the action of ultrasound to induce transfection of the indicated target therapeutic nucleic acid into the indicated ciliary muscle. 2. The pharmaceutical composition according to claim 1, wherein said target therapeutic nucleic acid is a deoxyribonucleic acid (DNA) molecule or a ribonucleic acid (RNA) molecule. The pharmaceutical composition according to claim 1 or 2, wherein said target therapeutic nucleic acid is inserted into a vector, such as a plasmid. The pharmaceutical composition according to claim 1, where the specified target nucleic acid encodes a polypeptide selected from the group consisting of enzymes, blood derivatives, hormones, lymphokines, cytokines, chemokines, anti-inflammatory factors, growth factors, trophic factors, neurotrophic factors, hematopoietic factors, factors angiogenesis, anti-angiogenic factors, metalloproteinase inhibitors, apoptosis regulators, blood coagulation factors, their receptors, in particular, soluble receptors, a peptide that is gonistom or antagonist of a receptor or of adhesion protein, antigens, antibodies, their fragments or derivatives and other necessary components kletok.5. The pharmaceutical composition according to claim 1, where the shell of the microbubbles �1. Фармацевтическая композиция, включающая микропузырьки эхо-контрастного агента и целевую терапевтическую нуклеиновую кислоту, для применения в способе лечения заболеваний глаз у субъекта, где указанный способ включает следующие стадии: i) доставку указанной фармацевтической композиции в цилиарную мышцу субъекта и ii) подвергание области, в которую доставлена фар
